Literature DB >> 12598027

Liver imaging with MDCT and high concentration contrast media.

Audrey L Spielmann1.   

Abstract

Liver imaging has advanced greatly over the last 10 years with helical CT capability and more recently the addition of multidetector-row CT (MDCT). Multidetector CT technology facilitates imaging at faster speeds with improved image quality and less breathing artifact [Abdom. Imaging 25 (2000) 643]. Exquisite three-dimensional data sets can be obtained with thin collimation providing improved lesion detection, multiplanar imaging, and the ability to perform CT angiography of the liver and mesenteric vessels. New challenges arise with this advance in technology including safety considerations. The radiation dose to the patient has increased with MDCT and this is compounded by the ability to perform multi-phase liver imaging. Furthermore, issues of contrast media administration require reconsideration including optimal timing and rate of administration, the total volume of contrast needed and the ideal iodine concentration of the contrast media. Recently, the use of high concentration contrast media (HCCM) has been explored and study results to date will be reviewed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12598027     DOI: 10.1016/s0720-048x(02)00361-3

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  2 in total

1.  64-Slice multidetector row CT angiography of the abdomen: comparison of low versus high concentration iodinated contrast media in a porcine model.

Authors:  N-S Holalkere; K Matthes; S P Kalva; W R Brugge; D V Sahani
Journal:  Br J Radiol       Date:  2010-11-16       Impact factor: 3.039

2.  Comparison of enhancement and image quality: different iodine concentrations for liver on 128-slice multidetector computed tomography in the same chronic liver disease patients.

Authors:  Byoung Goo Jo; Yun Gyu Song; Sang Goon Shim; Young Wook Kim
Journal:  Korean J Intern Med       Date:  2015-12-23       Impact factor: 2.884

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.